[SCHEDULE 13G/A] Relay Therapeutics, Inc. SEC Filing
Commodore Capital and related filers reported beneficial ownership of 13,350,000 shares of Relay Therapeutics (RLAY), representing 7.8% of the outstanding common stock as of June 30, 2025. The Schedule 13G/A names Commodore Capital LP, Commodore Capital Master LP, and managing partners Michael Kramarz and Robert Egen Atkinson as joint filers. The Firm acts as investment manager to Commodore Capital Master LP and the managing partners exercise investment discretion. The filing states the position was not acquired to change or influence control and attaches a Joint Filing Agreement.
Commodore Capital e i soggetti correlati hanno dichiarato la propriet脿 effettiva di 13.350.000 azioni di Relay Therapeutics (RLAY), pari al 7,8% del capitale sociale in circolazione alla data del 30 giugno 2025. Il Schedule 13G/A indica come co-dichiarante Commodore Capital LP, Commodore Capital Master LP e i partner gestori Michael Kramarz e Robert Egen Atkinson. La societ脿 svolge il ruolo di gestore degli investimenti per Commodore Capital Master LP e i partner gestori esercitano discrezionalit脿 sugli investimenti. Nell鈥檌stanza si precisa che la posizione non 猫 stata acquisita per modificare o influenzare il controllo e viene allegato un Accordo di Deposizione Congiunta (Joint Filing Agreement).
Commodore Capital y los presentadores relacionados declararon la titularidad beneficiaria de 13.350.000 acciones de Relay Therapeutics (RLAY), equivalentes al 7,8% del capital social en circulaci贸n a fecha 30 de junio de 2025. El Schedule 13G/A nombra como filers conjuntos a Commodore Capital LP, Commodore Capital Master LP y a los socios gestores Michael Kramarz y Robert Egen Atkinson. La firma act煤a como gestora de inversiones de Commodore Capital Master LP y los socios gestores ejercen discrecionalidad en las inversiones. La presentaci贸n indica que la posici贸n no se adquiri贸 para cambiar o influir en el control y adjunta un Acuerdo de Presentaci贸n Conjunta (Joint Filing Agreement).
旖旊霃勳柎 旌愴敿韯�(Commodore Capital) 氚� 甏�霠� 鞝滌稖鞚鸽摛鞚� 2025雲� 6鞗� 30鞚� 旮办 Relay Therapeutics(RLAY) 氤错喌欤� 13,350,000欤�, 歃� 氚滍枆欤检嫕鞚� 7.8%鞐� 雽�頃� 鞁れ鞝� 靻岇湢毳� 鞁犼碃頄堨姷雼堧嫟. Schedule 13G/A 靹滊鞐愲姅 瓿惦彊 鞝滌稖鞚胳溂搿� Commodore Capital LP, Commodore Capital Master LP, 攴鸽Μ瓿� 毵る媹歆� 韺岉姼雱堨澑 Michael Kramarz鞕� Robert Egen Atkinson鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 韼岇潃 Commodore Capital Master LP鞚� 韴瀽 鞖挫毄靷靹� 頇滊彊頃橂┌, 毵る媹歆� 韺岉姼雱堧摛鞚� 韴瀽 瓴办爼 甓岉暅鞚� 頄夓偓頃╇媹雼�. 鞝滌稖靹滌棎電� 頃措嫻 歆�攵勳澊 歆�氚瓣秾 氤�瓴� 霕愲姅 鞓來枼 氇╈爜鞚� 鞎勲媹鞐堨潓鞚� 氇呾嫓霅橃柎 鞛堨溂氅�, 瓿惦彊 鞝滌稖 頃╈潣靹�(Joint Filing Agreement)毳� 觳秬頄堨姷雼堧嫟.
Commodore Capital et les d茅posants associ茅s ont d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 13 350 000 actions de Relay Therapeutics (RLAY), repr茅sentant 7,8 % des actions ordinaires en circulation au 30 juin 2025. Le Schedule 13G/A d茅signe Commodore Capital LP, Commodore Capital Master LP et les associ茅s gestionnaires Michael Kramarz et Robert Egen Atkinson comme d茅posants conjoints. La soci茅t茅 agit en tant que gestionnaire d鈥檌nvestissement pour Commodore Capital Master LP et les associ茅s gestionnaires exercent la discr茅tion en mati猫re d鈥檌nvestissement. Le d茅p么t indique que la position n鈥檃 pas 茅t茅 acquise dans le but de modifier ou d鈥檌nfluencer le contr么le et joint un accord de d茅p么t conjoint (Joint Filing Agreement).
Commodore Capital und verbundene Einreicher meldeten den wirtschaftlichen Besitz von 13.350.000 Aktien von Relay Therapeutics (RLAY), was 7,8 % der ausstehenden Stammaktien zum 30. Juni 2025 entspricht. Das Schedule 13G/A benennt Commodore Capital LP, Commodore Capital Master LP sowie die gesch盲ftsf眉hrenden Partner Michael Kramarz und Robert Egen Atkinson als gemeinsame Einreicher. Die Gesellschaft fungiert als Investmentmanager f眉r Commodore Capital Master LP, und die gesch盲ftsf眉hrenden Partner 眉ben die Anlageentscheidungsbefugnis aus. In der Meldung wird angegeben, dass die Position nicht zur 脛nderung oder Beeinflussung der Kontrolle erworben wurde, und eine Joint Filing Agreement liegt bei.
- None.
- None.
Insights
TL;DR: Commodore reports a meaningful passive stake in RLAY (7.8%) under Schedule 13G/A; disclosure is routine but material for holders.
The filing discloses a non-control, passive aggregate stake of 13,350,000 shares (7.8%) in Relay Therapeutics as of June 30, 2025. This is a standard Section 13 reporting form indicating shared voting and dispositive power among the filers and clarifies the investment manager relationship. For investors, the filing provides transparency on a sizeable holder but does not indicate an activist intent or control transaction.
TL;DR: Joint filing shows coordinated ownership and voting/dispositive sharing but affirms no purpose to change control.
The Schedule 13G/A lists joint filing parties and specifies shared voting and dispositive power over the 13.35M shares. The certification states the holdings were not acquired to influence control, consistent with a passive investor filing. The presence of a Joint Filing Agreement and signatures from managing partners confirms coordination in reporting, which is important for governance disclosure even if no control intent is claimed.
Commodore Capital e i soggetti correlati hanno dichiarato la propriet脿 effettiva di 13.350.000 azioni di Relay Therapeutics (RLAY), pari al 7,8% del capitale sociale in circolazione alla data del 30 giugno 2025. Il Schedule 13G/A indica come co-dichiarante Commodore Capital LP, Commodore Capital Master LP e i partner gestori Michael Kramarz e Robert Egen Atkinson. La societ脿 svolge il ruolo di gestore degli investimenti per Commodore Capital Master LP e i partner gestori esercitano discrezionalit脿 sugli investimenti. Nell鈥檌stanza si precisa che la posizione non 猫 stata acquisita per modificare o influenzare il controllo e viene allegato un Accordo di Deposizione Congiunta (Joint Filing Agreement).
Commodore Capital y los presentadores relacionados declararon la titularidad beneficiaria de 13.350.000 acciones de Relay Therapeutics (RLAY), equivalentes al 7,8% del capital social en circulaci贸n a fecha 30 de junio de 2025. El Schedule 13G/A nombra como filers conjuntos a Commodore Capital LP, Commodore Capital Master LP y a los socios gestores Michael Kramarz y Robert Egen Atkinson. La firma act煤a como gestora de inversiones de Commodore Capital Master LP y los socios gestores ejercen discrecionalidad en las inversiones. La presentaci贸n indica que la posici贸n no se adquiri贸 para cambiar o influir en el control y adjunta un Acuerdo de Presentaci贸n Conjunta (Joint Filing Agreement).
旖旊霃勳柎 旌愴敿韯�(Commodore Capital) 氚� 甏�霠� 鞝滌稖鞚鸽摛鞚� 2025雲� 6鞗� 30鞚� 旮办 Relay Therapeutics(RLAY) 氤错喌欤� 13,350,000欤�, 歃� 氚滍枆欤检嫕鞚� 7.8%鞐� 雽�頃� 鞁れ鞝� 靻岇湢毳� 鞁犼碃頄堨姷雼堧嫟. Schedule 13G/A 靹滊鞐愲姅 瓿惦彊 鞝滌稖鞚胳溂搿� Commodore Capital LP, Commodore Capital Master LP, 攴鸽Μ瓿� 毵る媹歆� 韺岉姼雱堨澑 Michael Kramarz鞕� Robert Egen Atkinson鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 韼岇潃 Commodore Capital Master LP鞚� 韴瀽 鞖挫毄靷靹� 頇滊彊頃橂┌, 毵る媹歆� 韺岉姼雱堧摛鞚� 韴瀽 瓴办爼 甓岉暅鞚� 頄夓偓頃╇媹雼�. 鞝滌稖靹滌棎電� 頃措嫻 歆�攵勳澊 歆�氚瓣秾 氤�瓴� 霕愲姅 鞓來枼 氇╈爜鞚� 鞎勲媹鞐堨潓鞚� 氇呾嫓霅橃柎 鞛堨溂氅�, 瓿惦彊 鞝滌稖 頃╈潣靹�(Joint Filing Agreement)毳� 觳秬頄堨姷雼堧嫟.
Commodore Capital et les d茅posants associ茅s ont d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 13 350 000 actions de Relay Therapeutics (RLAY), repr茅sentant 7,8 % des actions ordinaires en circulation au 30 juin 2025. Le Schedule 13G/A d茅signe Commodore Capital LP, Commodore Capital Master LP et les associ茅s gestionnaires Michael Kramarz et Robert Egen Atkinson comme d茅posants conjoints. La soci茅t茅 agit en tant que gestionnaire d鈥檌nvestissement pour Commodore Capital Master LP et les associ茅s gestionnaires exercent la discr茅tion en mati猫re d鈥檌nvestissement. Le d茅p么t indique que la position n鈥檃 pas 茅t茅 acquise dans le but de modifier ou d鈥檌nfluencer le contr么le et joint un accord de d茅p么t conjoint (Joint Filing Agreement).
Commodore Capital und verbundene Einreicher meldeten den wirtschaftlichen Besitz von 13.350.000 Aktien von Relay Therapeutics (RLAY), was 7,8 % der ausstehenden Stammaktien zum 30. Juni 2025 entspricht. Das Schedule 13G/A benennt Commodore Capital LP, Commodore Capital Master LP sowie die gesch盲ftsf眉hrenden Partner Michael Kramarz und Robert Egen Atkinson als gemeinsame Einreicher. Die Gesellschaft fungiert als Investmentmanager f眉r Commodore Capital Master LP, und die gesch盲ftsf眉hrenden Partner 眉ben die Anlageentscheidungsbefugnis aus. In der Meldung wird angegeben, dass die Position nicht zur 脛nderung oder Beeinflussung der Kontrolle erworben wurde, und eine Joint Filing Agreement liegt bei.
